Nov 2, 4:19 PM ET
Celanese furnished prepared remarks and a slide deck for its third quarter 2026 earnings, showing adjusted earnings per share of $1.65, up 23% from the prior year, and free cash flow of $461 million. The company raised its full-year 2026 free cash flow outlook to $750 million to $800 million and expects full-year adjusted EPS of approximately $6.00 to $6.25. Management also said a sale of a further 19% stake in the Nutrinova joint venture to Mitsui, for about $152 million, is expected to close in the coming weeks.
- Q3 2026 adjusted EPS of $1.65, up 23% from the same period last year; free cash flow of $461 million
- Full-year 2026 free cash flow outlook raised to $750 million to $800 million
- Full-year 2026 adjusted EPS expected at approximately $6.00 to $6.25
- Net debt-to-operating EBITDA was 4.9x at quarter end, with a target of about 4.7x at the end of 2026
Read the filing on SEC.gov ↗
Nov 2, 4:17 PM ET
Celanese reported third quarter 2026 net sales of $2.6 billion, up 6% from a year earlier, and adjusted earnings per share of $1.65 versus $1.34 a year earlier. The company raised its 2026 free cash flow outlook to $750 to $800 million and expects full-year 2026 adjusted earnings per share of approximately $6.00 to $6.25, which gives shareholders a clearer view of earnings and cash generation for the year.
- Q3 2026 net sales $2.6 billion, up 6% year over year; U.S. GAAP diluted EPS $0.68 and adjusted EPS $1.65
- Full-year 2026 adjusted EPS outlook of approximately $6.00 to $6.25; free cash flow outlook raised to $750 to $800 million
- Agreement to sell an additional 19% of Nutrinova joint venture to Mitsui & Co. for about $152 million in cash, expected to close in Q4 2026
- Investor Event scheduled for December 9, 2026 in Florence, Kentucky
Read the filing on SEC.gov ↗
Sep 16, 5:00 PM ET
Celanese Corporation's Board increased its size from 10 to 11 members and elected Luis Fernandez-Moreno as a director, effective September 16, 2026. The filing describes him as independent under SEC and NYSE standards, with a background in specialty chemicals, and says he has not yet been appointed to any board committee.
- Board expanded from 10 to 11 members; Fernandez-Moreno serves until the 2027 Annual Meeting of Shareholders
- Board determined he is independent under SEC rules and NYSE listing standards; 10 of 11 directors are independent
- Previously served as SVP at Ashland, Inc. (2013-2017) and is a director at Ingevity Corporation since 2016
- No committee assignments yet; compensated under the company's non-management director practices
Read the filing on SEC.gov ↗
Aug 4, 4:20 PM ET
Celanese reported second quarter 2026 net sales of $2.8 billion, up 18 percent sequentially, and adjusted earnings per share of $2.45, compared with $1.43 a year earlier. Its U.S. GAAP diluted EPS from continuing operations fell to $1.15 from $1.89 a year earlier, and management expects third quarter adjusted EPS of about $1.35 to $1.75, moderating from the second quarter.
- Net sales $2.752 billion in Q2 2026 vs. $2.337 billion in Q1 2026 and $2.532 billion in Q2 2025
- Adjusted EPS $2.45 vs. $0.85 in Q1 2026 and $1.43 in Q2 2025; management called it the highest in nearly three years
- Q3 2026 adjusted EPS expected at approximately $1.35 to $1.75; full-year 2026 adjusted EPS of approximately $6.00 and free cash flow of $700 to $800 million reaffirmed
- Q2 free cash flow was $140 million, down from $311 million in Q2 2025
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.